FunctionInhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles.
Tissue specificityConstitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine.
Involvement in diseaseDefects in APOC3 may be a cause of hyperalphalipoproteinemia (HYPALIP) [MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL).
Sequence similaritiesBelongs to the apolipoprotein C3 family.
Post-translational modificationsO-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan.
Sandwich ELISA - Anti-Apolipoprotein CIII antibody (Biotin) (ab21024)Image from Wang Y et al., J Lipid Res. 2011 Jun;52(6):1265-71. Epub 2011 Mar 2. Fig 2.; doi: 10.1194/jlr.D011148; June 2011, The Journal of Lipid Research, 52, 1265-1271.
Sandwich ELISA, detecting Apolipoprotein CIII levels in Human or cynomolgus monkey serum, using ab21024 as detection antibody.
Anti-human Apolipoprotein CIII polyclonal antibody (ab21032) was added to an ELISA plate and incubated overnight at 4°C. Blocking buffer was added and incubated for 1 hour at room temperature. 50 µl of serum or standard was added to each well and incubated for 2 hours at room temperature. After washing, 50 µl/well of detection antibody (ab21024 at 1 µg/ml) was added and incubated at room temperature 1 hour followed by 50 µl/well of Streptavidin-HRP (ab64269). After color development, the absorbance was read at 450nm.
References for Anti-Apolipoprotein CIII antibody (Biotin) (ab21024)
This product has been referenced in:
Wang Y et al. Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum. J Lipid Res52:1265-71 (2011).
Read more (PubMed: 21371998) »
Dernick G et al. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays. J Lipid Res52:2323-31 (2011).
Read more (PubMed: 21971713) »